DrugPatentWatch Database Preview

Details for Patent: 8,329,216

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,329,216 protect, and when does it expire?

Patent 8,329,216 protects OPANA ER and is included in two NDAs.

This patent has forty-eight patent family members in sixteen countries.

Summary for Patent: 8,329,216

Title:	Oxymorphone controlled release formulations
Abstract:	The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.
Inventor(s):	Kao; Haui-Hung (Syosset, NY), Baichwal; Anand R. (Wappingers Falls, NY), McCall; Troy (Smyrna, GA), Lee; David (Chadds, PA)
Assignee:	Endo Pharmaceuticals Inc. (Chadds Ford, PA)
Application Number:	11/427,438
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,329,216
Patent Claim Types: see list of patent claims	Formulation; Compound; Dosage form; Use; Composition; Delivery;

Drugs Protected by US Patent 8,329,216

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021610-001	Jun 22, 2006		DISCN	Yes	No			Y
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	201655-001	Dec 9, 2011		DISCN	Yes	No			Y
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021610-005	Feb 29, 2008		DISCN	Yes	No			Y

International Family Members for US Patent 8,329,216

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	359077
Austria	376832
Australia	2002316582